Eyetech is very proud of its internationally renowned Scientific
Advisory Board. This board of world-class leaders in retinal
disease provides Eyetech with the guidance needed to develop
clinical trials, as well as creating a strong tie between
academic medicine, clinicians, and itself.
Anthony P. Adamis, M.D
Chief Scientific Officer; Co-Founder; Senior Vice President for Research
A leading expert on ocular vascular disease and ocular drug delivery, Dr. Adamis is best known for his co-discovery of the role that vascular endothelial growth factor (VEGF) plays in neovascularization and vascular permeability related to various diseases of the eye. His findings sparked important research advances in the treatment of such conditions as macular degeneration and diabetic retinopathy and continue to shape the course of research in these areas today. Dr. Adamis has authored over 100 publications. Prior to joining Eyetech, Dr. Adamis was an Associate Professor of Ophthalmology at the Harvard Medical School and served as a Principal Investigator and Co-Director of the Retina Research Institute for Diabetic Retinopathy and Macular Degeneration at Massachusetts Eye and Ear Infirmary, a teaching affiliate of Harvard Medical School. Dr. Adamis' affiliation with these institutions dates back to 1989, when he began his clinical and research fellowships at the Massachusetts Eye and Ear Infirmary. Dr. Adamis also completed a vascular biology fellowship with Dr. Judah Folkman at the Children's Hospital of Boston and later served as a Principal Investigator in the Surgical Research Laboratory at Children's Hospital. He received his M.D. degree from the University of Chicago and completed his residency in ophthalmology at the University of Michigan.
Mark Blumenkranz, M.D. - Stanford
Professor & Chairman of Ophthalmology at Stanford University
Dr. Blumenkranz is a world-renowned expert in retinal diseases and Professor and Chairman of Ophthalmology at Stanford University. He is a member of the Macula Society for which he served on the Executive Committee and the Association for Research in Visual Science and Ophthalmology (ARVO) where he was Chairman of the Retinal Section. He is currently on the Ophthalmic Drug Committee for the American Academy of Ophthalmology, and the Liaison Committee to Ophthalmic Devices Panel FDA. Dr. Blumenkranz is also either a reviewer, or on the editorial board of leading Ophthalmology journals including Ophthalmology, Archives of Ophthalmology, RETINA and Graefe's Archives for Clinical and Experimental Ophthalmology. Dr. Blumenkrantz has been a consultant for numerous pharmaceutical companies concerning drugs for macular degeneration.
Evangelos S. Gragoudas, M.D. - Harvard
Professor of Ophthalmology, Harvard Medical School
Dr. Gragoudas is Professor of Ophthalmology and the Director of Retinal Service at the Massachusetts Eye & Ear Infirmary, the teaching affiliate of Harvard Medical School. He is a world-renowned expert on age-related macular degeneration as well as choroidal melanomas. Dr. Gragoudas has served for eight years as a founding member of the Steering Committee of the Pharmacological Therapy for Macular Degeneration Study Group. He is considered a senior member of the retinal community and has lectured throughout the world. Along with Dr. Joan Miller, Dr. Gragoudas is acknowledged to be a pioneer in the use of photodynamic therapy ("PDT") in the treatment of AMD.
Morton Goldberg, M.D. - Johns Hopkins
Professor and Chairman of Ophthalmology at the Johns Hopkins University School of Medicine
Dr. Goldberg is Professor and Chairman of Ophthalmology at the Johns Hopkins University School of Medicine and directs the Wilmer Eye Institute. He has spent over thirty years investigating four major areas of eye disease: vascular retinopathies, laser therapy, trauma, and diseases of an inherited, metabolic, or congenital nature. Dr. Goldberg has served as Chairman for departments of ophthalmology for over thirty years (nineteen at the University of Illinois at Chicago and eleven at the Wilmer Eye Institute of Johns Hopkins University in Baltimore).
Joan Miller, M.D. - Harvard
Professor of Ophthalmology, Harvard Medical School
Dr. Miller is a world-renowned retinal specialist and basic scientist. She is a Professor of Ophthalmology at the Harvard Medical School. Dr. Miller is well known for being a pioneer in the pre-clinical and clinical development of PDT for AMD. She has also worked extensively in ocular angiogenesis research, including work on vascular endothelial growth factor (VEGF) with Dr. Adamis.
Lawrence A. Yannuzzi, M.D. - Columbia
Professor of Clinical Ophthalmology at Columbia University
Dr. Yannuzzi is a graduate of Harvard College and Boston University Medical School where he was recently honored as a distinguished alumnus. He has been acclaimed as a world-renowned retinal specialist with a particular interest in macular degeneration, diabetic retinopathy, and unusual chorioretinal diseases. Dr. Yannuzzi is also an investigator for the National Institutes of Health, an instructor and spokesman for the American Academy of Ophthalmology, editor of several prestigious ophthalmic text books, a Professor of Clinical Ophthalmology at Columbia University, the Vice-Chairman of the Department of Ophthalmology and Director of the Medical Retinal Service at the Manhattan Eye, Ear & Throat Hospital. Dr. Yannuzzi is considered one of the pioneers of medical retinal diseases, including macular degeneration.
|
